Indolent systemic mastocytosis (ISM) is one of the five subtypes of systemic mastocytosis, a condition characterized by the ...

Cogent Biosciences, Inc. topline results for phase 2/3 studies on bezuclastinib targeting systemic mastocytosis & GIST are ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In a study of 116 patients with systemic mastocytosis (SM), a rare mast cell disease, about 1 in 5 participants ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

Avapritnib has been approved to treat advanced systemic mastocytosis and indolent systemic mastocytosis and gastrointestinal stromal tumors with a platelet-derived growth factor receptor alpha (PDGFRA ...

In a study of 116 patients with systemic mastocytosis (SM), a rare mast cell disease, about 1 in 5 participants progressed to an advanced form of SM, incurring greater healthcare costs along the way.